Orion and Propeller Health have established a collaboration to offer a custom sensor and mobile app to digitally monitor medication use with Easyhaler — a metered-dose dry powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Developed by Orion and available across Europe, Easyhaler is a line of…
The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients. According to a press release from developer Mylan, the therapy, called Wixela Inhub (fluticasone propionate and salmeterol inhalation powder),…
Bevespi Aerosphere (glycopyrronium/formoterol fumarate), a therapy developed by AstraZeneca, has been approved by the European Commission as a maintenance treatment for adults with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is a combination of two bronchodilators (glycopyrronium and formoterol fumarate) delivered twice daily in a fixed dose…
Treatment administration has started in the second part of a Phase 2 trial evaluating the safety and efficacy of Synairgen‘s inhaled therapeutic candidate SNG001 in patients with chronic obstructive pulmonary disease (COPD) with a confirmed flu or cold virus. SNG001 is an inhaled interferon-beta (IFN-beta) therapy developed to help…
Inhaling vaporized cannabis does not improve breathlessness or exercise endurance in patients with advanced chronic obstructive pulmonary disease (COPD), according to a small Canadian study. The study reporting the findings, “Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced COPD: A randomized controlled…
Get regular updates to your inbox.